Purification and characterization of the NS3 serine protease domain of hepatitis C virus expressed in Saccharomyces cerevisiae

被引：0

作者：

Markland, W ^{[1
]}

Petrillo, RA ^{[1
]}

Fitzgibbon, M ^{[1
]}

Fox, T ^{[1
]}

McCarrick, R ^{[1
]}

McQuaid, T ^{[1
]}

Fulghum, JR ^{[1
]}

Chen, WY ^{[1
]}

Fleming, MA ^{[1
]}

Thomson, JA ^{[1
]}

Chambers, SP ^{[1
]}

机构：

[1] VERTEX PHARMACEUT INC, CAMBRIDGE, MA 02139 USA

来源：

JOURNAL OF GENERAL VIROLOGY | 1997年 / 78卷

关键词：

D O I：

暂无

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

cDNA encoding the putative core of the hepatitis C virus NS3 serine protease domain (residues 1-181 of NS3; NS3(181)) was expressed as an N-terminally (His)(6)-tagged fusion protein in Saccharomyces cerevisiae. NS3(181) protease activity was found in soluble cell lysates, and the N-terminal metal-chelating domain facilitated the efficient purification of active enzyme, using immobilized metal affinity chromatography. The purified NS3(181) protease activity was characterized by assaying the trans-cleavage of in vitro transcription-translation generated substrates, and subsequently a previously unobserved cleavage site within the NS5A region was identified. The inhibitory effect of known protease inhibitors was also examined. It is hoped that availability of this method for the expression and purification of the NS3(181) protease will facilitate the development of anti-hepatitis C therapies.

引用

页码：39 / 43

页数：5

共 50 条

[31] SAR and pharmacokinetic studies on phenethylamide inhibitors of the hepatitis C virus NS3/NS4A serine protease
Malancona, S
Colarusso, S
Ontoria, JM
Marchetti, A
Poma, M
Stansfield, I
Laufer, R
Di Marco, A
Taliani, M
Verdirame, M
Gonzalez-Paz, O
Matassa, VG
Narjes, F
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (17) : 4575 - 4579
[32] Probing the substrate specificity of hepatitis C virus NS3 serine protease by using synthetic peptides
Zhang, RM
Durkin, J
Windsor, WT
McNemar, C
Ramanathan, L
Le, HV
JOURNAL OF VIROLOGY, 1997, 71 (08) : 6208 - 6213
[33] A high throughput assay for identification of hepatitis C virus NS3 serine protease inhibitors.
Zemel, R
Berdichevsky, Y
Bachmatove, L
Kunin, M
Golan-Goldhirsh, A
Tur-Kaspa, R
Benhar, I
HEPATOLOGY, 2001, 34 (04) : 423A - 423A
[34] Prime site binding inhibitors of a serine protease:: NS3/4A of hepatitis C virus
Ingallinella, P
Fattori, D
Altamura, S
Steinkühler, C
Koch, U
Cicero, D
Bazzo, R
Cortese, R
Bianchi, E
Pessi, A
BIOCHEMISTRY, 2002, 41 (17) : 5483 - 5492
[35] Constraints on hepatitis C virus (HCV) NS3 serine protease genetic heterogeneity and evolution.
Soler, M
Penin, F
Ray, SC
Dhumeaux, D
Pawlotsky, JM
HEPATOLOGY, 2001, 34 (04) : 439A - 439A
[36] Proteolytic activity of NS3 serine proteinase of hepatitis C virus efficiently expressed in Escherichia coli
Shoji, I
Suzuki, T
Chieda, S
Sato, M
Harada, T
Chiba, T
Matsuura, Y
Miyamura, T
HEPATOLOGY, 1995, 22 (06) : 1648 - 1655
[37] Analysis of the domain interactions between the protease and helicase of NS3 in dengue and hepatitis C virus
Rosales-Leon, L.
Ortega-Lule, G.
Ruiz-Ordaz, B.
JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2007, 25 (05): : 585 - 594
[38] Redesigning the substrate specificity of the hepatitis C virus NS3 protease
Failla, CM
Pizzi, E
DeFrancesco, R
Tramontano, A
FOLDING & DESIGN, 1996, 1 (01): : 35 - 42
[39] Hepatitis C virus NS3/4a protease inhibitors
McCauley, John A.
Rudd, Michael T.
CURRENT OPINION IN PHARMACOLOGY, 2016, 30 : 84 - 92
[40] A ribonuclease zymogen activated by the NS3 protease of the hepatitis C virus
Johnson, R. J.
Lin, Shawn R.
Raines, Ronald T.
FEBS JOURNAL, 2006, 273 (23) : 5457 - 5465

← 1 2 3 4 5 →